Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,610 | 2 | 64.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,440 | 1 | 35.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $1,440 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $1,350 | 1 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $1,260 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,790 | 2 | PFIZER INC. ($1,440) |
| 2022 | $1,260 | 1 | JAZZ PHARMACEUTICALS INC. ($1,260) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,440.00 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 12/19/2022 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Consulting Fee | Cash or cash equivalent | $1,260.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 216 | 448 | $322,872 | $52,786 |
| 2022 | 4 | 164 | 399 | $311,909 | $49,795 |
| 2021 | 2 | 64 | 129 | $106,581 | $17,997 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 89 | 303 | $234,219 | $38,346 | 16.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 49 | 49 | $53,165 | $7,864 | 14.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 37 | 47 | $27,119 | $4,122 | 15.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 16 | 23 | $4,209 | $1,721 | 40.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 25 | 26 | $4,160 | $732.40 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 84 | 315 | $243,495 | $39,092 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 54 | 54 | $58,590 | $8,246 | 14.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 15 | 19 | $3,477 | $1,492 | 42.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 11 | $6,347 | $964.99 | 15.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 107 | $82,711 | $14,422 | 17.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $23,870 | $3,575 | 15.0% |
About Dr. Claire Mulvey, M.D
Dr. Claire Mulvey, M.D is a Hematology & Oncology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2013. The National Provider Identifier (NPI) number assigned to this provider is 1962845198.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Claire Mulvey, M.D has received a total of $4,050 in payments from pharmaceutical and medical device companies, with $2,790 received in 2024. These payments were reported across 3 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($2,610).
As a Medicare-enrolled provider, Mulvey has provided services to 444 Medicare beneficiaries, totaling 976 services with total Medicare billing of $120,578. Data is available for 3 years (2021–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location San Francisco, CA
- Active Since 04/08/2013
- Last Updated 06/10/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1962845198
Products in Payments
- LORBRENA (Drug) $1,440
- RYBREVANT (Drug) $1,350
- ZEPZELCA (Drug) $1,260
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Francisco
Dr. Terence Friedlander, Ms, MS
Hematology & Oncology — Payments: $248,592
Pamela Munster, Md, MD
Hematology & Oncology — Payments: $98,260
Dr. Caroline Behler, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $64,653
David Oh
Hematology & Oncology — Payments: $57,997
Dr. Paul Volberding, Md, MD
Hematology & Oncology — Payments: $51,997
Dr. Alain Algazi, M.d, M.D
Hematology & Oncology — Payments: $24,175